Bortezomib Patent Expiration
Bortezomib is Used for treating multiple myeloma patients who have not responded to previous therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc
Bortezomib Patents
Given below is the list of patents protecting Bortezomib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bortezomib | US11679119 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US11752164 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US12005069 | Bortezomib compositions | Sep 23, 2042 | Maia Pharms Inc |
| Bortezomib | US8962572 | Bortezomib formulations | Nov 03, 2032 | Fresenius Kabi Usa |
| Velcade |
US6713446 (Pediatric) | Formulation of boronic acid compounds |
Jul 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade |
US6958319 (Pediatric) | Formulation of boronic acid compounds |
Jul 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade | US6713446 | Formulation of boronic acid compounds |
Jan 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade | US6958319 | Formulation of boronic acid compounds |
Jan 25, 2022
(Expired) | Takeda Pharms Usa |
| Velcade |
US5780454 (Pediatric) | Boronic ester and acid compounds |
Nov 03, 2017
(Expired) | Takeda Pharms Usa |
| Velcade | US5780454 | Boronic ester and acid compounds |
May 03, 2017
(Expired) | Takeda Pharms Usa |
| Velcade | US6083903 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6297217 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6617317 | Boronic ester and acid compositions |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US6747150 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
| Velcade | US7119080 | Boronic ester and acid compounds, synthesis and uses |
Oct 28, 2014
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list recent legal activities going on the following patents of Bortezomib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Patent Issue Date Used in PTA Calculation Critical
| 12 Sep, 2023 | US11752164 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752164 |
| Recordation of Patent Grant Mailed Critical
| 12 Sep, 2023 | US11752164 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
| Email Notification Critical
| 12 Sep, 2023 | US11752164 |
| Email Notification Critical
| 24 Aug, 2023 | US11752164 |
| Issue Notification Mailed Critical
| 23 Aug, 2023 | US11752164 |
| Electronic Review Critical
| 10 Aug, 2023 | US11752164 |
| Email Notification Critical
| 10 Aug, 2023 | US11752164 |
Bortezomib's Family Patents
